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ABSTRACT
Allergic diseases have been described already in 900 AD but today allergic diseases have reached
epidemic proportions. About 30% of the world population is affected. Typical allergic symptoms of
the immune system’s reaction to allergens are runny nose, red eyes or skin reactions like itching,
eczema, urticaria, as well as more severe symptoms like asthma and anaphylactic reactions. The
overall aim of this thesis was to identify and characterize new pet allergens and to use these to
improve diagnostics and prediction of pet allergy. Furthermore, to provide a relevant platform, a
mouse model reflecting chronic asthma, for the development of novel treatment strategies for cat
allergy.
In the first paper we studied dog saliva as a source of new allergen molecules for improved
diagnostics of allergy to dog. We show that there are at least 12 protein bands in dog saliva that are
recognized by IgE antibodies from dog-allergic patients. Several of those bands were not identified
in dog dander extract. Furthermore, we demonstrate that about one-fifth of patients with symptoms
to dog, but lacking IgE antibodies to dog dander, were IgE positive to saliva. Dog saliva was shown
to be a significant allergen source that should be taken into account for improved diagnostics of dog
allergy. Combining dog dander and dog saliva or spiking dog dander extract with dog saliva would
be beneficial for developing enhanced dog allergy diagnostics.
In the second paper of this thesis we investigated the prevalence of sensitization to the novel cat
allergen Fel d 7 in 94 cat-sensitized patients and elucidated Fel d 7’s allergenicity and cross-
reactivity with the homolog major dog lipocalin allergen Can f 1 on an epitope level. More than a
third of the Swedish cat dander-sensitized patients, 39%, were IgE positive to Fel d 7 and we could
show that Fel d 7 is a biologically active allergen. Our results demonstrate that Fel d is cross-
reactive with Can f 1 and indicate that Fel d 7 has epitopes in common with Can f 1 which
contributes to the co-sensitization observed in patients with allergy to cat and dog. Also, Can f 1
peptides spanning the Can f 1 sequence were used to map Fel d 7 binding epitopes in a 3D model
based on the known structure of a human lipocalin homolog.
Paper III describes the association between sensitization patterns to individual cat and dog allergen
molecules during childhood and symptoms to these furry animals up to 16 years of age. We
investigated sensitization to individual cat and dog allergen molecules in childhood through
adolescence using the BAMSE (Barn/Children Allergy/Asthma Milieu Stockholm Epidemiologic
study) birth cohort. Sera and questionnaire data from 779 randomly collected children at 4, 8 and 16
years were examined. IgE reactivity to cat and dog allergen molecules were analyzed with the
MeDALL (Mechanisms for the Development of ALLergy) chip. This is the first study to elucidate
the usefulness of analyzing the individual cat and dog allergen molecules as predictors of cat and
dog allergy development from childhood to adolescence. We report that IgE to Fel d 1 is as good as
IgE to cat extract for diagnosis of cat allergy and IgE to Can f 1 is superior to IgE to dog allergen
extract for diagnosis of dog allergy. Thus, molecular-based allergy diagnostics may offer new
opportunities for improving diagnosis of pet allergy and in particular allergy to dog.
The last paper presents a relevant model for cat allergen-induced asthma in mice, exhibiting features
of human chronic disease. Female BALB/c mice were presensitized with rFel d 1 adsorbed to Alum
and subsequently challenged intranasally (i.n.) with cat dander extract (CDE) three consecutive
days per week during five weeks. The new animal model displays hallmarks of chronic allergic
asthma mimicking human disease, e.g. airway hyperresponsiveness, a mixed neutrophilic and
eosinophilic inflammatory response in the lung, proinflammatory cytokines and remodeling in lung
tissue. This paper provides a relevant model for studying chronic allergic disease induced by a
natural airway allergen. Thus, the model is suitable for testing novel strategies for cat allergy
vaccination, for evaluating and developing new treatments of human disease.
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11 THE IMMUNE SYSTEM
1.1 HISTORIC INTRODUCTION
The immune system has evolved to protect us from harmful foreign substances and has
developed with us since we became multi-cellular organisms. The word ‘immunity’ comes
from the Latin immunis and means ‘cannot be touched’. Immunity to disease was noted as
early as 430 BC by Thucydides in Athens, where plague survivors resisted repeated infection
after their initial exposure. However, it was not until the 1500th century that the Turks and
Chinese, and finally Edward Jenner in 1798 in England, deliberately induced immunity to
smallpox by inoculation with dried smallpox virus and cowpox virus, respectively. Since this
advancement, medicine has become even more aware of the importance of our immune
system.[1]
1.2 INNATE AND ADAPTIVE IMMUNITY
1.2.1 The Innate immune system
The immune system is comprised of two parts working together; the more primitive innate
immunity and the later, evolved adaptive immunity. The innate immunity is encoded in our
genes and specializes in protecting and quickly eliminating common pathogens by physical,
chemical and molecular barriers. To our immediate help against pathogens, we have an outer
barrier of epithelia on our skin and mucosal surfaces inside our body together with a
protective bacterial layer, microbiome, on all surfaces including healthy bronchus. If a
pathogen breaches the outer defense, our innate immunity forms a first line of defense with
anti-microbial substances, phagocytosis, cellular responses, cytokines and the complement
system that respond within seconds to hours. The response is mainly inflammatory, and
inflammation is characterized by increased vascular permeability and blood flow leading to
heat, pain, redness and swelling, or calor, dolor, rubor and tumor in Latin. This inflammation
gives access to infiltrating immune cells to the attacked area. Key cells in the innate immunity
are Natural killer (NK)-cells, Neutrophils, Macrophages (Mφ) and Dendritic Cells (DCs). [1]
A new and lesser explored group of innate immune cells are innate lymphoid cells (ILCs) that
are divided in types similar to T-cell classification, described later. The most well-known
ILCs is the NK-cell (ILC1), ILC2s are related to T helper type 2 cells and relevant for
allergies [2, 3]. The innate immunity uses preformed receptors to quickly initiate a primary
immune response when stimulated by their ligands. These are more primitive pattern
recognition receptors (PRRs) that respond to damage-associated molecular patterns (DAMPs)
and pathogen-associated molecular patterns (PAMPs). The PRRs, like the Toll-like
receptors (TLRs), are germline encoded and inherited as an evolutionary protection against
known pathogens [4]. However, the pathogens often mutate to adapt and escape our innate
immune system. [5]
21.2.2 The Adaptive immune system
Through the parallel evolution with microorganisms we have developed a second immune
defense, the adaptive immune system, with T-cells and B-cells and the ability to recognize
almost any foreign antigen by having random antigen receptors. When lymphocytes are
developed, B-cells in the bone marrow and T-cells in the thymus, combinations of hundreds
of gene segments of variable regions of their antigen receptors are joined. This creates
thousands of variations of the variable regions on the heavy and light chains of the receptor
that is unique to every cell. The variation is further amplified by junctional diversity because
nucleotides are added or subtracted in the gene segment-joining process. Hundreds of
millions of combinations are created by this combinational diversity of the antigen receptor.
Most B and T-cell receptors (BCRs and TCRs) will not recognize anything, but when a
pathogen is recognized by the receptor these cells undergo selection and proliferation.
However, before any pathogen or antigen (Ag) can be recognized they need to be presented
to the receptors. The presentation bridges between the innate and the adaptive immunity.
Macrophages, some B-cells and especially DCs are specialized to effectively monitor their
surroundings by constantly engulfing, or phagocytizing, it and are termed “professional
antigen presenting cells” (pAPCs). Many cell types, especially during inflammation, have the
ability to function as APCs but are less effective. The antigens are taken up, processed
enzymatically and presented by Major Histocompatibility Complex (MHC) class I and class
II to T-cell receptors in the lymph nodes, which may start an adaptive immune response. [1]
Pathogens if in the cell cytosol are processed and presented to on MHC class I on all
nucleated cells initiating CD8+ cytotoxic T-cell response to kill infected or damaged cells. In
the exogenous pathway, phagocytized pathogens are presented to CD4+ helper T -cells on
MHC class II on pAPC only. The CD4+ -cells can then differentiate into many functions
including effector T-cells, memory T-cells, or regulatory T-cells. [6]
1.3 HUMORAL AND CELLULAR IMMUNITY
1.3.1 Humoral immunity
Adaptive immunity is divided in humoral- and cellular immunity. Humoral immunity is
antibody-based. Naïve B-cells undergo a selection process during development in the bone
marrow (however their origin in birds, bursa of Fabricus, was discovered earlier and gave
rise to the name “B”-cell) that leads to the expression of a single BCR, i.e. a membrane
bound antigen-specific immunoglobulin.[1] Naïve B-cells have not found their specific Ag
and have not been activated yet. Circulating in secondary lymphatic tissues (lymph nodes and
spleen), they are activated upon encounter of antigens binding to a specific BCR and enter
germinal centers where they undergo affinity maturation toward the Ag and class switch
recombination (CSR) to an immunoglobulin (Ig) isotype (see below). Orchestrated by
presentation of extra cellular antigen on MHC class II, CD4+ T-helper-cells activate B-cells
via their BCRs which differentiate into either plasma cells that produce antigen specific
3antibodies or into long-lived B-cells with specific BCRs recognizing the Ag and make our
defense both faster and stronger at subsequent encounters. [7] This immunologic memory is
the basics of vaccination in T-cell dependent B-cell response. B-cell receptors are membrane
bound immunoglobulins (Ig) of five classes or isotypes; IgA, IgD, IgE, IgG and IgM. There
are antigens that can evoke T-cell independent B-cell response but only IgM and no memory
response. Immunoglobulins are glycoproteins that consist of two light chains joined by
disulfide bonds with two heavy chains forming a Y-shape. Variable regions on the tips of the
heavy and light chains form the antigen-binding site and bind the antigen, while the constant
region of the heavy chain defines the class, which in turn determines the effector mechanism
of the different Igs. All mature B-cells start by expressing IgM, but binding of the antigen
together with co-activation from T-cells activates the B-cells to class switching into more
specialized IgA, IgG or IgE antibodies better suited to fight particular antigens. Secreted Igs,
or antibodies (Ab), are central in immune recognition and in mounting immune responses to
pathogens.[1]
1.3.2 Cellular immunity
The other part of adaptive immunity is the cell-mediated immunity that does not rely on
antibodies, but on T-cells and the induction of phagocytes and cytokines. It includes cytotoxic
CD8+ T-cells (Tcyt-cells) and CD4+ helper 1 T-cells (Th1) that are able to kill cells infected
by intracellular viruses or bacteria. Specific CD8+ T cell responses are primed by APCs in
secondary lymphatic tissues. This activation is orchestrated by MHC class I presenting
intracellular antigen to naïve CD8+ cytotoxic T-cells that kill cells recognized by their TCRs.
CD4+ Th1-cells are activated via MHC class II, leading to IFNγ production, which in turn
activates macrophages and increases their microbicidal activity. One important part of the
immune system and cell mediated killing in particular is tight control. Mechanisms like
feedback loops and homeostasis usually protects the body from our immune system going out
of control. [3]
1.3.3 Th1/Th2 paradigm
Since the original presentation of the Th1/Th2 paradigm in 1986 [8] the helper T-cells have
been divided into, and seen as a balance and competition between, two Th subsets. These Th
subsets, Th1 and Th2, are focused on protecting the host against intracellular microbes and
extracellular helminths etc., respectively. Th1 immunity consists of cells with the linage
marker Tbet that typically produce the cytokine IFNγ, while Th2 immunity consists of cells
expressing the linage marker GATA-3 that typically produce IL-4, IL-5 and IL-13, which
induce anti-body production. Lately, it has become more and more clear that this
classification is oversimplified. More subclasses have been identified and the plasticity
among Th subsets is greater than it was first thought to be. The Th17 subset is a third distinct
but plastic linage with RORγt positive cells that produce the signature cytokine IL-17 and are
specialized in fighting extracellular bacteria and fungi.[3, 9] Other Th-cell subsets that have
been established are Th9[10, 11] and Th22[12], producing the signature cytokines IL-9 and
4IL-22, respectively, and expressing the transcription factors IRF4/PU.1 (Th9) and the aryl
hydrocarbon receptor (AhR) (Th22).[3]
1.3.4 T-regulatory cells
Tolerance, as mentioned earlier, is a key concept in the immune system. T-regulatory (Treg)
cells are commonly defined as CD25high, CD4 and Foxp3 positive and CD127 negative T-
cells [13]. These mainly refer to thymus-derived, or natural, Treg cells. Peripheral induced, or
adaptive, Treg cells may be Foxp3 positive or negative. Treg cells have the ability to end an
inflammatory state to keep homeostasis, influence (i.e. dampen) other cells and maintain
peripheral tolerance. Tregs regulate other immune cells by e.g. producing inhibitory
cytokines like IL-35, IL-10 and TGF-β, or by cell contact through e.g. inhibitory surface
molecules like CTLA-4 that blocks CD80 and CD86 co-stimulatory molecules.[14]
1.4 ALLERGY
1.4.1 History of allergy
Allergic diseases have been described already in 900 AD when the Persian physician Rhazi
described seasonal rhinitis [15], but it took a long time before the modern nomenclature was
coined. In 1902, the French physiologists Richet and Portier observed that dogs experience
immediate anaphylaxis and even death when exposed to a second dose of a small protein
toxin of sea anemones. Instead of giving protection, or phylaxis, as expected, the prior
injections made the immune system hypersensitized.[16] The term allergy was finally
introduced in 1906 by the Austrian pediatrician Pirquet, and refers to allos ’other‘ and ergon
’work‘.[17] IgE, which is central in allergic disease, was first described as ‘reagin’ in 1922
and characterized as IgE in 1966. [18, 19]
1.4.2 Types of allergy
The prevalence of allergy is about 30%.[20-24] Typical allergy symptoms are runny nose, red
eyes or skin reactions like itching, eczema, urticaria, as well as more severe symptoms
like asthma and anaphylactic reactions. The nomenclature for allergic diseases has been
unified to allow scientists and different medical disciplines, as well as the public, to correctly
address allergic and hyper-reactivity problems.[25]
Allergy is a hypersensitivity initiated by an immunologic mechanism. There are non-allergic
hypersensitivities and allergic hypersensitivities; the latter is referred to as allergy. Allergic
hypersensitivity is in turn divided into IgE-mediated allergy and non IgE-mediated allergy
(Fig. 1). Atopy is connected to allergy and refers to individuals who are genetically
predisposed to produce IgE antibodies in serum to normally harmless environmental agents,
allergens. The definition of atopy is: “A personal or familial tendency to produce IgE
antibodies in response to low doses of allergens, usually proteins, and to develop typical
symptoms such as asthma, rhinoconjunctivitis, or eczema/dermatitis.”[25, 26] IgE-mediated
5allergy is the most common type of allergic hypersensitivity and the majority of patients are
atopic. There are however some exceptions; for example, wasp allergy is not linked to atopy.
Allergic contact dermatitis is an example of non IgE mediated hypersensitivity.[25, 27]
Figure 1. Classification of hypersensitivities and allergies. Re-Printed from and with curtesy
to S.G.O. Johansson.[25]
1.4.3 Allergic sensitization
The up-to-date explanation of allergy is that when certain individuals that are most often
atopic encounter an allergen for the first time, various parts of their immune system start to
overreact. Allergic reactions are overly-powerful, or faulty, responses to normally harmless
environmental antigens, or allergens. It is not known why some proteins become allergens.
PRRs like TLRs on APCs have been shown to interact with some allergens, possibly
mistaking them for pathogens. APCs migrate and present the allergen to T cells in the lymph
nodes.[1] The immune response depends on the location, the cytokine milieu around the cell
and the co-stimulatory signals. The IgE antibody production in allergy requires Th2 cells and
is inhibited by Th1 cells and INFγ.[5, 28] Also the route and dose to the allergen exposure
have importance. A low dose favors an allergic Th2 response and many common allergens
are inhaled and delivered to the lungs in low dose. [1, 29] DC mediated priming of naïve Th
cells into Th2 are very important in deciding over induction of Th2-cells and production of
proinflamatory cytokines in the induction of allergic reactions.[30] Th2 cells expand and
produce cytokines like IL-4, IL-5 and IL-13 that further promotes allergic inflammation, Th2
expansion, B cell class switch to production of IgE, recruitment, differentiation and
6maturation of basophils, mast cells and eosinophils. In this sensitization phase, IgE antibodies
are secreted into circulation and bind to the α-chain of the high-affinity receptors for IgE (i.e.
FcεRI) on the surface of mast cells and basophils. This results in these cells and the persons
becoming sensitized to that allergen.[1] In healthy individuals, Tregs help to suppress
reactions towards allergens, whereas allergic individuals have been shown to have an
impaired Treg response to allergens due to a Th2 cytokine milieu that inhibits Treg
development.[31]
1.4.4 Early phase reaction
In the effector phase of allergy, a new encounter with the allergen causes cross-linking of IgE
antibodies on sensitized mast cells and basophils. These cells are activated and within a few
minutes degranulate to release preformed and newly generated inflammatory mediators,
mainly histamine, heparin and proteases. Preformed pro-inflammatory cytokines like TNFα,
IL-2, IL-4, IL-5 and IL-13, together with chemokines, are released and stimulate the
production of more cytokines and chemokines while the degranulated mast cells and
basophils start producing leukotrienes and prostaglandins. The inflammatory response is
characterized by increased vascular permeability and blood flow, which leads to heat, redness
and swelling. This causes bronchoconstriction, airway mucus secretion, itching, rashes and
possible systemic anaphylaxis vasodilation.[1] Anaphylaxis or anaphylactic shock is not the
most common allergic symptom but is the most severe. Systematic effects give an acute fall
in blood pressure followed by contraction of smooth muscles with stress on the heart and
lungs that can be fatal within minutes of contact with the allergen. [32, 33]
1.4.5 Late phase reaction
Several hours after allergen exposure, the activation of allergen-specific T-cells can in some
patients induce a late phase allergic reaction with edema of the skin (after a skin prick test),
blockage of the nose, and narrowing of the airways and mucus hypersecretion. The reactions
are induced by cytokine-mediated recruitment and activation of large numbers of Th2 cells,
neutrophils, eosinophils, basophils and resident mast cells.[1] Anaphylaxis can also be
delayed and occur during the late phase.[33]
1.4.6 Chronic phase
If the allergic inflammation is sustained over an extended period of time, extracellular matrix
and structural cells can be affected to the point that chronic inflammation can lead to tissue
remodeling and fibrosis, coupled with the development of allergic asthma. [33] The sustained
eosinophilic Th2-polarized inflammatory state with excess of e.g. IL-4 and IL-5 starts a
process where excess of extra cellular matrix production and fibrous connective tissue forms
a scared area and fibrosis permanently damage to the lung tissue.[28, 34]This damage leads
to progression of asthma and decrease of flexibility of the lung with asthma symptoms as
result.
71.4.7 Etiology
1.4.7.1 Genetics and epigenetics
About half the western urban population is atopic and the majority of people with allergy are
atopic. [35] Atopic families and individuals have a concentration of genes or gene variants in
areas related to endogenous induction of inflammation associated with allergic asthma.
Allergic rhinitis, grass sensitization and cat allergy have been coupled with other genes
typically related to Interleukins and MHC/HLA. However, as in all complex diseases, the
genetic contribution is only one part of the reason why symptoms occur; it is possible to
develop allergies without being atopic. Another part is epigenetics, first used by Conrad Hal
Waddinton in 1940 for the layer above the genes regulating somatic gene expression
modifications.[36] Environmental exposures can influence the epigenome effecting e.g. pro-
inflammatory cytokines related to allergic disease and the changes can be inherited.[2, 37]
However, inherited factors alone cannot explain the etiology of allergic disease.
1.4.7.2 Hygiene hypothesis
There has been a marked increase in allergic diseases in children and young adults [38] that
has reached epidemic proportions worldwide, and the incidence of these diseases is
continuing to increase in association with a western metropolitan lifestyle. [35, 39, 40]
Environmental exposure to potential allergens early in life or during pregnancy probably has
a key role in the development of allergy[41, 42]. Increased prosperity, health, new diets and
environment are all hypothesized to contribute to the increasing number of allergic diseases
due to under-stimulation of the immune system, making it over-sensitive. This explanation is
referred to as the ‘Hygiene hypothesis’. Countries now experiencing the development seen in
the western world a few decades ago are also accompanied by increases in allergic diseases,
e.g. the Baltic countries and, more recently, China. Now more and more data supports the
hygiene hypothesis. [43-45]
1.5 ALLERGENS
1.5.1 Allergen families
There are major and minor allergens. The definition of a major allergen is that IgE
sensitization to the allergen is found in over 50% of the patients allergic to the allergen source
it originates from. Minor allergens have a prevalence of sensitization of less than 50%.[46,
47] Allergens are named after the Latin names of their origin and are, as a rule, numbered
according to the order they were discovered and reported to WHO/ International Union of
Immunological Societies (IUIS).[46, 48, 49] Allergens are proteins or glycoproteins, typically
globular proteins and often with enzymatic activity. The enzymatic activity can be protease
activity, as in the major mite (Dermatophagoides pteronyssinus) allergen Der p 1, by which
e.g. tight junctions are digested facilitating the allergen access across epithelial barriers.[50-
52] Other allergens have enzymatic activity that stimulates other paths. Many allergens are
8similar to their human counterpart proteins, while they need to be different enough to be
allergenic. With respect to mammalian allergens, lipocalins is the largest allergen family, and
more than 50% of the total allergens identified from furry animals belong to this protein
family.[53] They are found in many body fluids and secretions including urine, tears, saliva,
serum and dander. All lipocalins share a conserved structure and folding pattern, even if they
often only share some sequence identity.[54-56] The only other main pet allergens not
belonging to the lipocalin family are the major cat (Felis domesticus) allergen Fel d 1, a
salivary secretoglobulin[57, 58], and the major dog (Canis familiaris) allergen Can f 5, a
urinary kallikrein[59]. Serum albumin is another common allergen family that is present in
most pets.[40, 60-65]
1.5.2 Allergen Extracts
Allergen extracts are mixtures of allergens and non-allergenic material, e.g. enzymes and
other proteins extracted from an allergen source. Pet allergen extracts are typically prepared
by extracting proteins from hair and skin scrape i.e. dander. Saliva, and urine to some extent,
are transferred to fur and can often be found in these kinds of extracts. Some allergens may
be poorly represented in crude allergen extracts among non-allergenic molecules or
unproportional amounts of other allergens from the same source.[66] Smaller animals such as
mites or ticks, or food and plant allergens that are often present in the allergen source, may be
present in the extract and pet extracts have been shown to cause false positive results, due to
contamination.[67-69] These impurities can even lead to new sensitizations during treatments
with extracts.[70] The advantage of extracts is that they resemble the allergen sources in
composition and are similar to how we are exposed to the allergens in real life. Unfortunately,
even with attempts to standardize production the content and the quality of allergen extracts
have shown great variability.[66]
1.5.3 Cat allergens
Allergy to cats (Felis domesticus) is the second most common indoor allergy in the western
world for both children and adults. The major cat allergen is Fel d 1, which is a salivary
uteroglobin protein,[58, 71] is a very dominant cat allergen. Up to 95% of all cat-allergic
patients have IgE against Fel d 1.[72-74] Fel d 2 is a serum albumin, Fel d 3 a cystatin and
Fel d 4 a lipocalin. Fel d 5 is cat IgA and Fel d 6 cat IgM, which contains the carbohydrate
galactose-α-1,3-galactose (alpha-Gal)[75]. The newly identified Fel d 7 and Fel d 8 belong to
the lipocalin and salivary latherin family, respectively.[76, 77] The prevalence of IgE
reactivity  among patients allergic to cat for Fel d 2 is around 20%, Fel d 3: 10%, Fel d 4:
60%, Fel d 5: 40%, Fel d 6: NA, Fel d 7 38% and Fel d 8: 20%, summarized in [53].
91.5.4 Dog allergens
The major dog (Canis familiaris) allergen Can f 1 together with Can f 2, Can f 4 and Can f 6
belong to the lipocalin family.[54, 78-81] Can f 3 is serum albumin[82] and Can f 5 is
prostatic kallikrein. Can f 5 derived from dog urine was identified as a major allergen in 2009
and reported to be recognized by up to 70% of dog-sensitized patients.[59] The importance of
Can f 5 as a diagnostic marker for dog allergy is however questionable. The lipocalin Can f 6
is the most recently discovered dog allergen.[59, 78] The prevalence of IgE reactivity among
patients allergic to dog for Can f 1 is around 50%, Can f 2: 25%, Can f 3: 20%, Can f 4: 20%,
and Can f 6: 40%, summarized in [53].
1.5.5 Cross-reactive allergens
Cross-reactivity to allergens, i.e. IgE-binding to similar epitopes in different protein or to
homologous proteins, is often found among lipocalins and serum albumins in pets. The fact
that allergens from different furry animals often belong to the same allergen families has
raised questions about cross reactivity. Investigations have determined that these lipocalins
and serum albumins are responsible for most of the cross reactivity that is seen.[54, 78, 83-
86] The largest possibility to find cross activity is when the allergens have more than 60%
sequence identity.[78]
Epitope spreading is related to the progression of allergic disease and, much like cross
reactivity, is caused by IgE receptor presenting an allergen with a shared epitope to which the
allergic individual is already sensitized. This process can lead to sensitization to new adjacent
epitopes and new allergens if some epitopes are shared between the different allergens. [87,
88]
1.5.6 Recombinant allergens
Advances in molecular biology during the recent decades have enabled the generation of
recombinant allergens, with well-defined molecular, immunological and biological
characteristics.[89-91] The first allergen to be cloned was Der p 1in 1988.[92-94] This opens
up possibilities to produce standardized products of reliable purity. Genes of the allergens are
cloned into expression vectors and transformed in to Escherichia. Coli production systems
like e.g. BL-21. Recombinant (r) proteins can be produced consistently and with very high
purity, and are therefore very attractive for diagnostics as well as treatments and can help in
increasing specificity.[83, 95] Recently, allergenic molecules from the most important
allergen sources have become available as recombinant proteins.
1.6 ALLERGY TREATMENT
1.6.1 Symptomatic treatment
The first approach to relive allergic symptoms is avoidance of the allergen source, but some
allergens are hard to avoid. As a next step, a variety of medications are utilized for
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symptomatic therapy, e.g. anti-histamines, anti-leukotrienes and inhaled steroids.[1] These
kinds of treatments only give short term relief from the symptoms and lifelong treatment is
often needed. Acute anaphylaxis is treated by intramuscular adrenalin (epinephrine)
injections that relax respiratory smooth muscles and acts on the heart.[32] A drug given
exclusively in special cases such as severe allergic asthma with high IgE levels is the humanized
monoclonal antibody Omalizumab (Xolair). Its specificity is against circulating IgE and works by
blocking the IgE from binding to the IgE receptors on the mastcells and basophils. [96] However, a
lifelong treatment regime is not ideal.
1.6.2 Curative treatment
The word vaccination springs from ‘vacca,’ Latin for cow, and originates from the
phenomena of transferred immunity. It was described by E. A. Jenner in “An Inquiry into the
Cause and Effects of the Variolae Vaccinae” in 1798.[97] Allergen Specific Immunotherapy
(ASIT), lately termed allergy vaccination, is the only treatment that can cure allergic disease,
and it has been performed for over 100 years[98]. In 1911, the British scientist Leonard Noon
treated grass pollen allergic patients with grass extract. He injected patients with the extract
over several weeks in increasing amounts and successfully alleviated hay fever
symptoms.[99] ASIT has been proven to be a clinically effective treatment for allergic
disease.  It is the only disease-modifying therapy that can reduce allergic inflammation and
prevent the development of chronic disease.[100] Typically an adjuvant is used in ASIT to
increase to effect of ASIT. Alum is currently the adjuvant used in subcutaneous ASIT (SCIT),
but our research group and others has also evaluated other adjuvants and approaches for
better and safer ASIT. Alum mainly promotes Th2 immune responses [101], which is not
ideal in an allergy context, and its main function in allergy vaccines is to prevent systemic
spreading of the allergen. Moreover, a common adverse side effect to SCIT is granuloma
formation at the injection site, caused by alum [102]. The aim with an adjuvant in ASIT is to
modify the allergen-specific immune response to tolerate an allergen by changing the
immune response to the allergen from allergic Th2 to tolerogenic Treg or Th1 and by
induction of blocking IgG-antibodies that hinder allergen binding to IgE.[103-105] Most
commonly, ASIT is performed by subcutaneous injections of the allergen extract (SCIT).
Newer safer alternatives are sublingual immunotherapy (SLIT)[106, 107] and intralymphatic
immunotherapy (ILIT)[108] where tablet/drops are given orally or injections in to lymph
nodes, respectively. In the latter, sine it is given directly into the lymph node, only a very
small dose needs to be given reducing the risk of side effects. The oral route t is convenient
since patients can administer the tablets/drops themselves, but has shown to be less efficient
compared to SCIT.
However, traditional ASIT protocols similar to the SCIT original protocol by Noon are long,
up to five years, as well as time- and resource-consuming and are associated with risks of
both early and late adverse side effects.[109] In order to make the treatment attractive for
more patients that would benefit from ASIT, new safer and shorter treatment strategies with
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fewer injections and new administration routes are currently under development and
assessment. [95, 110-117] We implement the knowledge into a future treatment of allergy via
mouse models. Most mouse model are acute, meaning that they model the acute phase of
allergic disease but a few, including our, are chronic models that also mirror the chronic
stages of human allergic disease.

13
2 THESIS AIMS
The overall aim of this thesis is to identify and characterize new pet allergens and to use the
findings to improve diagnostics and the prediction of pet allergy. And furthermore, to provide
a relevant platform, a mouse model reflecting chronic asthma, for the development of novel
treatment strategies for cat allergy. The specific objectives of the four papers are:
Specific aims:
Paper I: To evaluate dog saliva as a source of new allergen molecules for improved
diagnostics of allergy to dog.
Paper II: To investigate the prevalence of sensitization to the novel allergen Fel d 7 in a
European cat-sensitized population and elucidate its allergenicity and cross-reactivity with the
dog allergen Can f 1 on an epitope level.
Paper III: To investigate the association between sensitization patterns to cat and dog
allergen molecules during childhood and symptoms to these furry animals up to 16 years of
age.
Paper IV: To establish a relevant model for cat allergen-induced asthma in mice, exhibiting
features of human chronic disease.
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3 METHODS
The methods used in the different papers included in this thesis are briefly described in this section
with reference to the papers where they are applied. Each paper contains a section with detailed
descriptions of the material and methods.
Enzyme-linked immunosorbent assay (ELISA)
ELISA was used to determine the content of e.g. antibodies or cytokines in fluids, e.g. sera or BAL.
Different types of ELISAs were used where an antigen or an antibody was coated. Inhibition
ELISAs were conducted with serial dilutions of inhibitors mixed with serum prior to the ELISA. A
reference standard for e.g. IgE or IgG was used when quantifying absolute levels. ELISA was used
in paper I, II and IV.
ImmunoCAP
A routine diagnostic method, ImmunoCAP, was used for determining allergen-specific IgE
(ImmunoCAP System; Phadia/Thermo Fisher, Uppsala, Sweden) in which an allergen molecule or
allergen extract is coupled to a solid phase. The allergen-specific IgE levels are given in kUA/L.
This method was used in paper I, II and IV.
Luminex
Luminex is a technique reminiscent of ELISA but that simultaneously measures and quantifies
multiple protein targets in a single fluid, e.g. serum, sample. This method was used in paper IV.
MeDALL chip
The MeDALL (Mechanisms for the Development of ALLergy) microarray is based on the, ISAC
technology.  The values are given in ISAC Units (ISU-E).  This method was used in paper III.
Protein production and purification
Genes of allergens of interest; Fel d 1, Fel d 7 and Can f 1, were cloned into expression plasmids
and transformed into Escherichia. Coli production systems. Bacterial pellets were solubilized and
purified by e.g. His-tag specificity on immobilized metal chelate affinity chromatography (IMAC)
and size. These methods were used in paper I, II and IV.
Biochemical characterization
Allergen proteins were analyzed by SDS-PAGE to verify molecular size and purity. Some gels were
used for immunoblotting or 2D-PAGE before mass spectrometry. These methods were used in
paper I and II.
Immunoblot
Proteins of interest were transferred from SDS-PAGE gels to membranes and detected using
specific antibodies and a secondary enzyme-conjugated detecting antibody. This method was
used in paper I
Mass spectrometry
Protein extracts from different sources were separated by 2D-PAGE. Protein dots of interest were
excited, trypsin digested and analyzed by LC-MS/MS (Liquid chromatography– Tandem mass
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spectrometry or) for identification. This method was used in paper II.
Mouse model
Different protocols were used in which mice were presensitized subcutaneously with alum-
adsorbed recombinant cat allergen Fel d 1, followed by intranasal challenges with cat dander extract
spiked with recombinant Fel d 1 or PBS. For reference, mice were presensitized and challenged
with ovalbumin following the same protocol. This method was used in paper IV.
Airway hyperresponsiveness measurements
Airway hyperresponsiveness (AHR) was analyzed by a direct invasive method, using a small
animal ventilator, FlexiVent. The airway response to increasing doses of metacholine is recorded
using computerized measurements of pressure and air flow. From these data lung physiological
parameters such as resistance and elastance can be calculated. This method was used in paper IV.
Bronchoalveolar lavage
Bronchoalveolar lavage (BAL) was performed directly after AHR measurement to assess the
inflammatory response to AW challenge.  Lungs of mice were flushed with PBS to collect BAL
cells and fluid (BALF) for differential cell counting and cytokine measurements, respectively. This
method was used in paper IV.
Lung remodeling analyses
At the end of the mouse protocol, lungs were subjected to histological analyses of inflammation and
tissue remodeling. Paraffin-embedded lung sections were stained by hematoxilin/eosin (HE) and
periodic acid-Schiff/Alcian blue reaction (PAS) for detection of infiltrating cells and mucus and
with Masson’s trichrome for analysis of connective tissue. This method was used in paper IV.
Quantitative PCR
At the end of the mouse protocol, lung tissue cDNA was amplified from mRNA expression of
particular genes e.g. Th2 cytokines (IL-4 and IL-5 mRNA expression) analyzed and quantified in
comparison to a reference gene. This method was used in paper IV.
Basophil activation test
In the basophil activation test (BAT), basophils were tested for reactivity and sensitivity to different
stimulants. Whole blood samples from allergic patients were incubated with serial dilutions of
allergen and then stained for the basophil marker CD203c and the degranulation marker CD63. This
method was used in paper I and II.
Rat basophil leukemia assay
Rat basophil leukemia (RBL) cells transfected with the human high-affinity IgE receptor FcεRI
were incubated with sera from sensitized patients and stimulated with different concentration of
allergens. Release of β-hexosaminidase from RBL cell was measured in ELISA. This method was
used in paper III.
Circular dichroism spectroscopy
Far and near UV circular dichroism (CD)-spectra were performed to obtain information on
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secondary and tertiary protein structures for protein characterization and to compare structures
between proteins. This method was used in paper II.
3D modeling
Sequences of allergen molecules of interest were compared using SWISS-MODEL to predict the
3D structure. This method was used in paper II.
Rabbit immunization
Peptide-specific IgG antibodies were obtained by immunizing rabbits three times with Can f 1-
derived synthetic peptides. This method was used in paper III.
Statistical analyses
Association between sensitization patterns to allergen molecules and symptoms were analyzed for
e.g. Odds Ratios (OR) and Positive/Negative predictive values (PPV/NPV). Results from treatment
groups from the mouse asthma model protocol were compared by Mann-Whitney U-test. These
methods were used in paper III and IV, respectively. In addition Spearman Correlation test (in paper
I,II) and linear regression as well as t-tests (in paper III) were used.
Ethical statement
All human studies and animal experiments conducted in paper I, II, III and IV were approved by the
local ethics committees. Written consent was obtained from all patients recruited for the basophil
experiments.
18
4 RESULTS AND DISCUSSION
4.1 IDENTIFICATION OF DOG SALIVA ALLERGENS AND THEIR
IMPROVMENT OF DOG ALLERGY DIAGNOSTICS [I]
In this paper, we studied dog saliva as a source of allergens for improved diagnosis of allergy
to dog. We compared dog saliva and dog dander extracts in western blot and observed that
the dog-allergic patients had IgE specific to many salivary proteins. There was a greater
abundance and diversity of IgE-binding proteins in dog saliva compared to dog dander
extract (Fig. 2). In dog dander extract, most of the patients recognized protein bands at
positions corresponding to sizes of known dog allergens. Contrastingly, at least 12 IgE-
binding proteins were detected in dog saliva and several of those were of molecular weight
sizes not recognized in the dog dander extract (Fig. 2).
Figure 2 SDS–PAGE and immunoblot analyses of dog saliva (S) pool (n = 14) and dog
dander (D) extract (Allergon). Immunoblot was developed with single dog-allergic patient’s
sera. m, Molecular weight markers; c, control (buffer); lanes 1–13, patient sera.
We looked further into the IgE binding in dog dander and dog saliva by a 2D-PAGE by using
a pool of dog allergic patient’s sera (n=13). The seven most prominent IgE binding spots
detected among dander (five) and saliva (two) samples were cut out, trypsin in-gel digested,
analyzed and identified by LC-MS/MS sequencing of peptides and database searches. From
the saliva sample five spots were analyzed, and Can f 1, 2, 3 and 6 peptides were identified in
one or more spots. We also found four new saliva allergen candidates in the dog saliva. These
were two BPI fold proteins and dog IgA heavy chain constant region. From the dog dander
extract two spots were analyzed, and Can f 1, 2, 3, 4 as well as Can f 6 together with BPIFA1
peptides were identified in one or both spots. Verifying the known allergens strengthen the
data on the new allergen candidates.
The majority of dog dander positive patient sera (44 of 59) were also IgE positive to dog
saliva in ELISA. More than one-third of these patients (23/59; 39%) had a higher IgE
reactivity to saliva than to dander. Among 55 dog dander negative patients with symptoms to
dog, 20% were IgE positive to dog saliva. As diagnosis of dog allergy in daily practice relies
on the clinical history of the patient together with diagnostics based on dog dander extract,
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our results have important clinical implications. We observed that the correlation between
IgE responses to saliva and dander in ELISA was r2 = 0.48 (P<0.0001) (Fig. 3), reflecting
that the two allergen sources are related, but more interestingly, that they also differ in their
allergen content. This gives the potential to utilize dog saliva for future improved diagnostics
of dog allergy. One approach would be to spike dog dander extract with dog saliva. Since
saliva is full of degradation enzymes and unstable, another option would be to apply the
newly identified dog allergens from saliva in component resolved diagnostic to get data on
the individual allergen molecules.
Figure 3 Correlation between IgE reactivity to dog dander (y-axis) and dog saliva (x-axis)
(n = 59); OD – optical density, r2 – correlation factor.
The allergenic activity of saliva was confirmed by basophil degranulation in three patients,
emphasizing that saliva is an allergen source. Interestingly, one of these patients was low or
non-responding to dog dander extract. Dog saliva gave rise to similar or higher basophil
activation than dog dander in all three patients. The results strengthen the importance of
improving dog dander based diagnostics by dog saliva. Other allergen sources, such as urine,
might also hold undiscovered dog allergens.  A recently discovered urinary major dog
allergen is Can f 5. However, Can f 5 is deposited on male dog hair and dander [59].
We analyzed saliva from different dog breeds and noted that there are great variations in the
IgE-binding profile where some had fewer IgE binding bands and the amount of different
proteins varied. Overall, a greater abundance and diversity of IgE-binding proteins was found
in dog saliva compared to dog dander extract. We showed that there are many false negative
results in current dog allergy. About one-fifth of patients with symptoms to dog, but lacking
IgE antibodies to dog dander, were IgE positive to saliva.
Taken together, we show that there are at least 12 protein bands in dog saliva that are
recognized by IgE antibodies from dog-allergic patients. Furthermore, we demonstrate that
about one-fifth of patients with symptoms to dog, but lacking IgE antibodies to dog dander,
were IgE positive to saliva. Thus dog saliva was shown to be a significant allergen source that
should be taken into account for improved diagnostics of dog allergy. Combining dog dander
and dog saliva or spiking dog dander extract with dog saliva would be beneficial for
developing enhanced dog allergy diagnostics.
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4.2 ALLERGENIC CHARACTERIZATION OF THE CROSS-REACTIVE
LIPOCALIN CAT ALLERGEN FEL D 7 [II]
In this paper, we studied the newly discovered cat lipocalin allergen Fel d 7 and report that it
is an important allergen in a Swedish cat sensitized population. As the primary structure of
Fel d 7 has a high sequence similarity and identity (63%) with Can f 1 we also investigated its
cross-reactivity with Can f 1. In SDS-PAGE we noted that both proteins appeared mainly as
monomers in line with earlier reports. The near and far UV circular dichroism (CD)-spectra
of rFel d 7 and rCan f 1 revealed similar secondary structure and tertiary structures.
More than a third of the Swedish cat dander-sensitized patients (37/94 individuals) were IgE
positive to rFel d 7. The figure is similar to the one reported among cat allergic patients from
Australia. The result  shows that the newly identified lipocalin Fel d 7 is an important
allergen in a Swedish cat sensitized population in addition to  the very dominating major cat
allergen Fel d 1 . The Fel d 7-positive sera were also analyzed for IgE to rCan f 1 and the
majority, 34 (89.2%), had IgE reactivity to rCan f 1 as well. We found a modest correlation (r
=0.58, P < 0.001) between the IgE levels to Fel d 7 and Can f 1, indicating that there is IgE
cross-reactivity between these two lipocalins.
Even though Fel d 7 has been accepted as an allergen by the WHO/ International Union of
Immunological Societies (IUIS) allergen nomenclature committee since 2011[76], its
biological activity has so far not been elucidated. We investigated the allergenic activity of
rFel d 7 by basophil activation test (BAT) using blood from cat allergic patients who were
IgE positive to Fel d 7 and found that Fel d 7 was able to stimulate basophil degranulation.
Thus, Fel d 7 is a biological active allergen. To further strengthen our finding we looked into
the biological activity of Fel d 7 in relation to Can f 1 by analyzing sera from 11 patients IgE-
positive to both rFel d 7 and rCan f 1 in a rat basophil leukemia (RBL) assay. We noted that
the allergens induced a varying degree of degranulation that was independent of the allergen-
specific IgE levels. We further explored the allergenic cross-reactivity between Fel d 7 and to
Can f 1 by inhibition ELISA using sera sensitized to rFel d 7 and rCan f 1. We found that the
degree of cross-reactivity varied between patients. Can f 1 was able to completely inhibit the
IgE binding to rFel d 7 in two out of five sera, whereas rFel d 7 was able to inhibit the
binding to rCan f 1 to 70% in two sera. The other sera showed lower degree or no inhibition.
The results indicate that Fel d 7 has epitopes in common with the major dog lipocalin allergen
Can f 1 which contributes to co-sensitization observed in patients with allergy to cat and dog.
We then aimed to identify the cross-reactive epitopes on Fel d 7 and Can f 1. Sera from
rabbits immunized with five overlapping Can f 1 peptides spanning the Can f 1 sequence
were used. We observed that peptides covering the C- and N-terminal epitopes gave rise to a
stronger binding to rFel d 7 than the other antisera. Based on the results we created a 3D
model, SWISS-MODEL, on the known model of human tear lipocalin/von Ebners gland
protein (VEGP). Figure 4 shows that the main epitopes shared between  Fel d 7 and Can f 1
are located at the C- and N-terminus (highlighted) which is consistent with our results from
the Can f 1 peptide antisera (Fig. 4B).  As Fel d 1 has shown not to account for all IgE
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binding to cat extract, a larger cat allergen panel is needed in diagnostics. With respect to
Fel d 7, we have shown that it is an important allergen in 39% of cat sensitized patients, and
contributes to the co-sensitization noted between cat and dog allergic patients.
Figure 4 Cross-reactive epitopes on Fel d 7 and Can f 1.
(A) 3D model of cross-reactive sequences, pink color corresponds to sequences present in
both pet lipocalins and the tear human lipocalin. Blue color is sequences present only in
rFel d 7 and rCan f 1. (B) Highlighted N- (Green) and
Cterminal (Red) ends.
4.3 PREDICTION OF PET ALLERGY IN ADOLESCENCE BY SENSITIZATION
PATTERNS TO CAT AND DOG ALLERGEN MOLECULES IN CHILDHOOD
[III]
We investigated sensitization to individual cat and dog allergen molecules in childhood
through adolescence using the BAMSE (Barn/Children Allergy/Asthma Milieu Stockholm
Epidemiologic study) birth cohort to identify risk markers for allergic symptoms to cat and
dog up to age 16. Sera and questionnaire data from 779 randomly collected children at 4, 8
and 16 years were used. IgE reactivity to cat and dog allergen molecules were analyzed with
the MeDALL (Mechanisms for the Development of ALLergy) chip. Allergy was defined as
reported rhinitis, conjunctivitis or asthma at exposure to cat or dog.
We first investigated the prevalence of IgE sensitization to cat and dog extract (ImmunoCAP)
and found that it increased over time, from 6.8% at 4 years to 19.8% at 16 years for cat and
from 5.1% to 22.9% for dog. Likewise, allergic symptoms to cat and dog increased during the
same period from 4.8% to 11.2% for cat and from 3.1% to 5.5% for dog. We also found that
the prevalence of IgE to any of the cat or dog allergen molecules increased and reached
nearly 15% and 22% at age 16 for any of dog or cat allergen molecules, respectively.
Interestingly, sensitization to Can f 5 (1.9-12.6% at 4-16 yrs) was more common than to
Can f 1 (1.9-5.5% at 4-16 yrs), but Can f 1 induced the highest IgE levels.
22
We next investigated IgE reactivity cross-sectionally and found that the IgE levels to Fel d 1
were significantly higher at each time point among children with symptoms to cat compared
to asymptomatic children. Even though 81% of children sensitized to a single dog allergen
molecule at 16 years had IgE reactivity to Can f 5, only about 10% of them reported
symptoms. We calculated positive predictive values (PPV) for symptoms among subjects
with IgE reactivity to cat or dog allergen extract or to the different pet allergen molecules. We
observed that IgE to Fel d 1 and to cat extract had similar PPV for cat allergy. However, IgE
to Can f 1 showed a higher PPV for dog allergy than IgE to dog extract. Thus, IgE testing
with just one cat allergen molecule, Fel d 1, is as good as testing IgE to cat allergen extract
and IgE to Can f 1 seems to have advantages over dog allergen extract. The results have
implication for diagnosing cat and dog allergy.
Next we elucidated IgE reactivity to the pet allergens longitudinally in relation to symptoms.
Only IgE to Fel d 1 at 4 and 8 years was significantly associated with increased risk of
symptoms to cat at 16 yrs (OR=13.7, 95% CI 8.3-22.7 after adjustment for the other cat
allergen molecules) (Fig. 5, lower part). With respect to dog allergen molecules, sensitization
to Can f 1 at 4 and 8 years was the only dog allergen significantly associated with symptoms
to dog at 16 years (OR=8.0, 95% CI 2.3-27.7 adjustment for other dog allergens)(Fig. 5,
lower part). Furthermore, we noted that sensitization to more than one pet allergen at 4 or 8
years significantly increased the likelihood of having pet allergy symptoms at 16 years
(Fig. 6). Thus, sensitization to Fel d 1 and Can f 1 at 4 and 8 years are risk markers for cat
and dog allergy at 16 years.
Figure 5 Longitudinal logistic regression. Crude and adjusted odds ratios (OR) for IgE
sensitizations to each cat and dog allergen (ISU-E≥0.3) at 4 and 8 years of age in relation
to reported cat/dog allergy 16 years of age. N=779.
*Adjusted for concomitant sensitization to the other cat or dog components, respectively.
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Figure 6 Likelihood (y-axis: percentage) of reporting symptoms to cat/dog at 16 years of
age depending on the number of IgE-reactive cat (Fel d 1, Fel d 2, Fel d 4) or dog (Can f 1,
Can f 2, Can f 3, Can f 5 and Can f 6) allergens and ImmunoCAP cat or dog extract
sensitization (x-axes) at 4 years.
This is the first study to elucidate the usefulness of analyzing individual cat and dog allergen
molecules as predictors of cat and dog allergy development from childhood to adolescence.
For diagnosis of cat allergy, IgE to Fel d 1 is as good as IgE to cat extract and IgE to Can f 1
is superior to IgE to dog allergen extract. Thus, molecular-based allergy diagnostics may
offer new opportunities for improving diagnosis of pet allergy and in particular allergy to
dog.
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4.4 DEVELOPMENT OF A MOUSE MODEL FOR CHRONIC ALLERGIC
ASTHMA [IV]
In Paper IV, we aimed to develop a protocol for induction of chronic allergic disease in mice,
in order to obtain a relevant model for studying novel treatment strategies for allergy to cat.
Female BALB/c mice were presensitized with rFel d 1 adsorbed to Alum and subsequently
challenged intranasally (i.n.) with cat dander extract (CDE) three consecutive days per week
during five weeks in the main optimized protocol (Fig. 7). As a reference, one group of mice
was subjected to the same protocol using chicken albumin (OVA) for sensitization and i.n.
allergen challenge. rFel d 1 sensitized and PBS-challenged mice served as negative controls.
Both the cat allergen and OVA models generated AHR in response to metacholine and
inflammation as demonstrated by histological analyses of the lung tissue. The OVA model
displayed typical signs of Th2 allergy with predominant influx of eosinophils and
lymphocytes in BAL, and elevated levels of Th2 cytokines in lung tissue (IL-5 protein levels
and IL-4 and IL-5 mRNA expression). In contrast, our cat allergen induced asthma model
showed a mixed type of allergic response, with enhanced total numbers of lymphocytes,
neutrophils and eosinophils in BAL, increased lung tissue IL-17a levels and elevated relative
mRNA expression of IL-17a, IL-4 and IFN- in the lung tissue. In a separate protocol, AW
inflammation and tissue remodeling was specifically studied by histological analyses of lung
tissue. Both the cat allergen- and OVA sensitization and challenge protocols resulted in high
inflammatory scores and both models exhibited signs of AW remodeling (Fig.8). Finally, the
allergen-specific antibody response was of a mixed Th1/Th2 type in the cat allergy model,
with elevated levels of IgE (not significant, p=0.56), IgG1 and IgG2a to Fel d 1 compared to
PBS-challenged control mice.
Figure 7 Presensitization (s.c. Alum-Fel d 1) and challenge (i.n. CDE) protocol.
We have previously developed an acute mouse model of allergy to cat.[118] The present
model displays hallmarks of chronic allergic asthma, such as AHR, a mixed neutrophilic and
eosinophilic infiltration in BAL similar to that in human allergic asthma, expression of the
proinflammatory Th17 cytokine IL-17a and signs of remodeling in lung tissue. A chronic
model for a chronic disease that is against a natural airway allergen, Fel d 1, and that more
closely resembles natural i.n. exposure is a big advancement in allergy models. Earlier
models were short acute models and/or with unnatural exposure by injections and/ allergens
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like OVA. Mouse models with OVA are skewed towards producing Th1 cytokines that do
not reflect human allergic, Th2, disease well [119]. This paper provides a relevant model for
studying chronic allergic disease induced by a natural airway allergen. Thus, the model is
suitable for testing novel strategies for allergy vaccination (i.e. ASIT) for evaluating and
developing new treatments of human disease.
Figure 8 Inflammation and tissue remodelling in lungs from mice (n = 4). a) Total
inflammation score based on the sum of scores (max score = 12) for the degree of
inflammatory cell infiltration, amount of inflammatory infiltrate, and of macrophages and the
area involved in lesions in HE-stained sections (left). Results from evaluation of PAS-stained
sections measuring the number of goblet cells ware estimated (middle) and Masson’s
trichrome-stained sections analyzing peribronchial and perivascular connective tissue was
analyzed (right). b) Representative sections from PBS-, CDE- and OVA-challenged mice
stained with HE.
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5 CONCLUSIONS
Paper I: We evaluated dog saliva as a source of new allergen molecules for improved
diagnosis of dog allergy. We found at least 12 protein bands in dog saliva that were
recognized by IgE antibodies of dog-allergic patients, and several of those were not found in
dog dander. This means that saliva has a greater diversity of IgE-binding proteins than dog
dander, in which only a few IgE-binding proteins corresponding to already known dog
allergens were detected. In dog saliva, four interesting new allergen candidates (BPIFA2,
mucin-5B and angiopoietin-related protein 5-like (ANGPTL5) and IgA heavy chain constant
region) were identified alongside known allergens. We also showed that current diagnostics
for dog allergy, using dog dander extract, generate many false negative results. About one-
fifth of patients with symptoms to dog, but lacking IgE antibodies to dog dander, were IgE
positive to saliva.
Thus, dog saliva was shown to be a significant allergen source, and the shortcomings of dog
dander extracts can be improved by adding dog saliva to the diagnostics of dog allergy.
Paper II: We investigated the novel allergen Fel d 7 and showed that it is a frequently
recognized allergen in a Swedish cat sensitized population. IgE antibodies to Fel d 7 were
found in 39% of cat sensitized patients and 89% of these were also sensitized to the major
dog allergen Can f 1. Thus, cross-reactivity between these homologous lipocalin allergens
was indicated. Fel d 7 was indeed shown to have a similar structure and to share B-cell
epitopes with Can f 1. The biological activity of Fel d 7 was confirmed in basophil activation
assays in cat allergic patients. We conclude that Fel d 7 may contribute to the co-sensitization
noted in cat and dog allergic patients. Our data will be important for aiding diagnosis of
allergy to dog and cat.
Paper III: We investigated the association between sensitization and symptoms to cat and
dog allergens in children up to 16 years of age using the BAMSE birth cohort. The data
showed that sensitization to Can f 1 and Fel d 1 during childhood was associated with
significant increased risks of symptoms to dog and cat, respectively, at 16 years after
adjusting for other dog/cat allergen molecules.
In addition, we found that IgE to Fel d 1 had similar positive predictive values (PPV) for cat
allergy as cat extract did. However, IgE to Can f 1 showed a higher PPV for dog allergy than
IgE to dog extract. Even though IgE to Can f 5 was more prevalent during childhood than
Can f 1, it showed weaker associations to dog allergy. Thus, we showed how to intrepret
sensitization to individual cat and dog allergens and use thereof in pet allergy diagnostics.
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Paper IV: We aimed to establish a mouse model for cat allergen-induced asthma that
resembles human disease more closely than current cat allergy models. We could show that a
protocol comprising pre-sensitization with Fel d 1/alum followed by repeated intranasal
challenges with cat dander extract resulted in a model that displayed hallmarks of chronic
allergic asthma. Furthermore, we demonstrated that the nature of the allergens used for
sensitization and challenge in the model was critical for the outcome of the immune- and
inflammatory response. While the commonly used model allergen OVA produced a typical
Th2-type of response, we observed that i.n. administration of cat allergen extract generated a
mixed response characterized by neutrophilic and eosinophilic inflammation and both Th2-
and Th17-type cytokine production in the lung. The cat allergen induced asthma model will
be a valuable tool for evaluating novel treatment strategies for cat allergy. In the longer run
by improving ASIT regimes we hope that they will induce long lasting cure and diminish the
need of symptomatic treatment.
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6 FUTURE PERSPECTIVES
Future allergy diagnostics will be based on individual allergen molecules reflecting the
natural allergen source. These allergen molecules will help to increase accuracy in allergy
diagnosis and prognosis. In paper 1, we showed that dog saliva is a significant allergen source
that should be added to dog dander for improved diagnostics of dog allergy. In the future, it
would be of great interest to investigate the usefulness of dog saliva in other populations.
Furthermore, whether children and adults with symptoms to dog have different IgE reactivity
to dog saliva would be another valuable question to elucidate for increasing our knowledge
regarding dog saliva in diagnosis. However, there are concerns with safety and protein
stability of dog saliva due to degradation of proteins. Therefore, proceeding with the allergen
candidates to identify novel proven allergens would be beneficial. Then, having had
confirmed one or many new dog saliva allergens that could be cloned and produced
recombinantly, would  enable spiking dog dander extract with relevant recombinant dog
allergens instead. The result of such an extract spiked with stable, characterized and well
purified proteins would address the safety and stability issues and be able to be implemented
in routine diagnostics, and in the future also for ASIT if we can improve the extract.
Cat allergy is a major problem worldwide. In paper II we show that Fel d 7 is an important
cat allergen in a Swedish cat sensitized population. It would be of great interest to investigate
its importance for asthma due to cat among children, which is an important pediatric problem.
As Fel d 7 shares epitopes with the lipocalin Can f 1 it would be valuable to elucidate its role
in cross-reactivity with lipocalins from other furry animals. Other lipocalins that are similar to
Fel d 7  is one in Panda with 68% identity and horse and pig VEGP with 62% and 58%
identity, respectively [76]. These have about as much sequence identity as Can f 1 and Fel d 7
do, and could be interesting in terms of cross-reactivity. The horse lipocalin is most relevant
for further studies in pet allergies. This would increase our understanding of how cross-
reactivity may translate into polysensitization.
Our 3D model reveals that the epitopes shared between Fel d 7 and Can f 1 are mainly
exposed on the N and C terminus of the proteins. Since the antibodies to linear peptides only
show linear surface antigens and cannot reach inside the structures or more complex
conformational epitopes, where different non-linear sequences form a surface epitope, these
would be interesting to explore. The 3D-model with the cross-reactive epitopes is a starting
point for further studies into the allergens, and their exact structure should be determined by
X-ray crystallography, where you also are able to visualize the interaction between
conformational epitopes and antibodies.
Crystal structure and data on Fel d 7 will be important for further investigations in the
structure and help in diagnostics, respectively. However, since Fel d 1 is so dominant the
interest of Fel d 7 in diagnostics would mainly be in finding cat sensitization in the few Fel d
1 negative patients and in pet cross-reactivity patients. Further studies are needed to elucidate
the clinical importance of Fel d 7.
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Using recombinant and natural purified allergens in molecular-based allergy diagnostics,
instead of extracts, offers not only new opportunities for improving diagnostics of allergy but
also for determining prognosis. We show that IgE to Fel d 1 and Can f 1 in childhood are
useful markers of cat and dog allergy in Swedish teenagers. Whether this holds true for birth
cohorts from other countries needs to be elucidated. Such results are of major clinical
importance with respect to treatment and avoidance. Our finding that some allergens, in
particular Fel d 1 and Can f 1, can be used as strong prognostic risk markers for the
development of allergy changes the future for doctors and ultimately patients to make wise
decisions in pet allergen avoidance that could help protect people from developing allergies
in the first place. One topic to follow up on is if information about early markers of future pet
allergy, the allergen component sensitization in childhood, can improve the outcome in
avoiding allergy development.
The presented mouse model for cat allergen-induced asthma exhibits hallmarks of chronic
allergic asthma and will provide a relevant platform for development of new treatment
strategies. As a next step, we would like to continue to test treatment regimes against cat
allergy in this model. The effect of allergy vaccines may be enhanced by adding an adjuvant.
One candidate Fel d 1 vaccine that we would like to evaluate is Fel d 1 produced by
virulence-attenuated Listeria monocytogenes (Lm). We have prepared a Fel d 1 vaccine
candidate, in which Fel d 1 is carried by an Lm vaccine vector, Lm-Fel d 1, in this way. The
gene for rFel d 1 has been cloned and transformed into Lm so that rFel d 1 is produced in vivo
in the host receiving intraperitoneal immunizations. This novel vaccine candidate could be
evaluated both in our previously established acute model for cat allergy [118] and more
carefully in the new chronic mouse model of cat allergy. The stimulation from Lm could
possibly be able to break the Th2 state of allergic disease since it is a strong
immunomodulatory agent, which is complex but partly inhibits Th2 response and induces a
Th1 response with IFNγ production.[120-123] Additionally, comparing the efficacy of Lm-
Fel d 1 with the traditional ASIT adjuvant Alum, Alum-Fel d 1, could be performed side-by-
side in our mouse models i.e. as in paper IV.
To conclude, this thesis is based on the application of pet allergen molecules, and spans from
allergen characterization to prediction of symptoms and to the development of an allergy
model for chronic airway disease. Paper I and II describe the usefulness of a forgotten
allergen source from dog and the allergenic relationship between lipocalins from different
allergen sources. Paper III shows how sensitization is linked to symptoms by analyzing
multiple allergen components, implicating that diagnostics and prediction of future symptoms
can be improved. Paper IV presents a new chronic mouse model of cat allergy for evaluation
of new treatments. In the longer run, improving ASIT regimes will induce long lasting cure
and diminish the need of symptomatic treatments.
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7 POPULÄRVETENSKAPLIG SAMMANFATTNING
Allergiska sjukdomar har beskrivits redan 900 e.Kr. men idag har allergiska sjukdomar blivit
så vanliga att de har nått epidemiska proportioner. Allergen är vanligen ofarliga proteiner
som vissa personer kan bli allergiska emot, dessa bildar antikropparav IgE typ mot allergenet
och sägs då vara sensibiliserade mot det allergenet. Runt 30 % av världens befolkning lider
idag av minst någon allergisjukdom. Typiska allergiska symptom t. ex. rinnande näsa, röda
ögon, hudreaktioner som klåda, eksem och nässelutslag, samt mer allvarliga symptom som
astma och akuta anafylaktiska reaktioner, kan uppkomma när vårt immunförsvar försöker
försvara oss mot ofarliga ämnen, allergener, i vår omgivning. Allergidiagnostiken baseras i
stort på allergenextrakt, och för diagnostik av pälsdjursallergi på extrakt från pälsen.
Extrakten är inte alltid så rena och kan vara svåra att standardisera, vilket får negativa effekter
på tillförlitligheten. Därför finns det ett behov att vidarutveckla diagnostiken för att göra den
mer tillförlitlig. Målet med denna avhandling är att förbättra diagnostiken för pälsdjursallergi
och att utveckla en modell där nya behandlingsmetoder kan studeras.
I det första arbetet studerades hundsaliv som en källa till nya allergena molekyler för
förbättrad diagnostik av allergi mot hund. Där visas att det finns minst 12 proteinband i
hundsaliv som känns igen av allergiframkallande s.k. IgE-antikroppar från hundallergiska
patienter. Hundpälsextrakt är inte tillräckligt bra på att diagnostisera hundsensibilisering i
allergitester. Det är känt att tester för hundallergi kan ge falskt negativa resultat. I vårt arbete
visade det sig att ungefär en femtedel av patienterna som får allergiska symptom av hund,
men saknar IgE-antikroppar mot hundpäls, hade IgE-antikroppar mot hundsaliv. Hundsaliv
visade sig vara en betydande allergenkälla som bör beaktas för att förbättra diagnostiken av
hundallergi. Att kombinera hundmjäll och hundsaliv eller spetsa hundpälsextrakt med
hundsaliv eller med allergen från saliv skulle vara fördelaktigt för att utveckla förbättrad
hundallergidiagnostik.
I det andra arbetet i denna avhandling undersöks förekomsten av allergi orsakat av det nya
kattallergenet ”Fel d 7” i 94 katt-sensibiliserade patienter. Vi analyserade Fel d 7s
allergiframkallande förmåga och dess förmåga att reagera på det liknade huvudallergenet i
hund, ”Can f 1”. Mer än en tredjedel av de svenska kattsensibiliserade patienterna, 39 %,
hade IgE antikroppar mot Fel d 7 och vi kunde visa att Fel d 7 är ett biologiskt aktivt allergen
som utlöser allergi reaktioner i celler från kattallergiska patienter. Våra resultat visar att Fel d
7 är korsreaktivt med Can f 1. Det innebär att de två allergenen har gemensamma
ytstrukturer, vilket förmodligen är en bidragande orsak till att patienter ofta är sensibiliserade
mot både katt och hund. Med hjälp av antikroppar riktade mot delar av Can f 1 kunde vi
dessutom visa vilka ytstrukturer som Fel d 7 binder till i en 3D-modell som skapades baserat
på en välstuderad mänsklig variant av proteinet.
I det tredje arbetet undersöks sambandet mellan sensibiliseringsmönster mot enskilda katt och
hund allergenmolekyler under barndomen och allergisymptom mot dessa pälsdjur upp till 16
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års ålder. Vi undersökte sensibilisering mot enskilda katt- och hund-allergenmolekyler i
barndomen till puberteten med hjälp av BAMSE (Barn Allergi / Astma Mijö Stockholm
Epidemiologi studien), en studie som har följt barn från de var 2-3 månader  upp till 16 år.
Blodprover och enkätdata från 779 slumpmässigt utvalda barn vid 4, 8 och 16 år användes.
IgE antikropps-reaktivitet mot katt- och hund-allergenmolekyler analyserades med ett nytt
diagnostiskt test, ett litet glas som innehåller allergenmolekyler från nästintill alla kända
allergenkällor. Detta är den första studien som belyser nyttan av att analysera de individuella
katt- och hund-allergen för att förutspå utveckling av allergi mot katt- och hund. För diagnos
av kattallergi visade sig antikroppar mot huvud allergenet i katt ”Fel d 1” vara lika bra som
kattextrakt. Huvud hund allergenet Can f 1 var överlägset hundallergenextrakt för att
diagnosticera allergi mot hund. Således kan allergidiagnostik med de enskilda allergenen
erbjuda nya möjligheter att förbättra diagnostiken för allergi mot sällskapsdjur, särskilt allergi
mot hund. Att man kan använda diagnostiken för att förutspå risken för att utveckla katt- eller
hundallergi i framtiden är av stor betydelse.
I det fjärde och sista arbetet presenterar en relevant sjukdomsmodell i möss för kattallergisk
astma, som uppvisar drag av kronisk sjukdom i människa. Möss sensibiliserades med
kattallergenet och provocerades därefter med extrakt från kattpäls under fem veckor för att
etablera allergi- och astmasymptom mot katt. Kattallergent är ett naturligt luftvägsallergen
vilka inte har använts för lite i tidigare djurmodeller för allergiska sjukdomar. Den nya
djurmodellen uppvisar inte bara akuta symptom som tidigare modeller utan även tecken på
kronisk allergisk astma, som luftvägsöverreaktivitet, en inflammation i lungan som liknar den
i mänsklig allergisk astma samt förändringar och förhårdningar i lungvävnad som
karakteriserar kronisk astma. Det här arbetet har gett en relevant kronisk modell för att
studera kronisk allergisk sjukdom. Således är modellen lämplig för att testa nya strategier för
allergivaccination, för att utvärdera och utveckla nya behandlingar av allergisk sjukdom hos
människor.
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